Knockdown of PERK promotes survival of luminal breast cancer cells treated with a combination of lapatinib (a tyrosine kinase inhibitor) and obatoclax (a pro-survival BCL-2 family inhibitor) by reducing pro-death autophagy [73]. Here, BCL2 is linked to breast cancer.